MEA SJS TEN Treatment Market - Industry Trends and Forecast to 2030 | Pharmaceutical_LifeSciense Market Research Report

Abstract

Summary

Middle East and Africa SJS/TEN treatment market is expected to reach USD 471.24 million by 2030 from USD 320.21 million in 2022, growing at a CAGR of 5.1% during the forecast period of 2023 to 2030. The new market report contains data for the historic year 2021, the base year of calculation is 2022 and the forecast period is 2023 to 2030. Market Segmentation: Middle East and Africa SJS/TEN Treatment Market, By Treatment (Medications, Support Care, Hospitalization, Isolation, Ointments, and Others), Diagnosis (Physical Exam, Skin Biopsy, Medical History, Blood Test, Cultures, and Others), Cause (Specific Treatment, Infection, and Others), Route of Administration (Oral, Parenteral, Topical, and Others), Drug Type (Branded and Generic), Therapy Area (Combination Therapy and Monotherapy), Patient Type (Geriatric, Adult, and Pediatric), End User (Hospitals, Specialty Clinics, Ambulatory Surgical Center, Homecare Setting, and Others), Distribution Channel (Retail Pharmacies, Direct Tender, and Others), Country (Saudi Arabia, South Africa, Bahrain, Kuwait, Oman, Qatar, U.A.E., Egypt, Israel, and Rest of Middle East and Africa) - Industry Trends & Forecast to 2030 Overview of Middle East and Africa SJS/TEN Treatment Market Dynamics: Driver • Increasing demand for early diagnosis of the disease Restrain • Limited availability of specialized care for SJS/TEN treatment Opportunity • Developing effective and safe treatments for SJS/TEN treatment Market Players: Some of the key market players operating in the Middle East and Africa SJS/TEN treatment market are listed below: • 3M • Cardinal Health • BD • Smith + Nephew • Novartis AG • Amneal Pharmaceuticals LLC. • Pfizer Inc. • Colgate-Palmolive Company • Merck & Co., Inc. • Mölnlycke Health Care AB. • Xttrium Laboratories • Schülke & Mayr GmbH • Purdue Pharma L.P. • eugia (Subsidiary of Aurobindo Pharma) • AdvaCare Pharma

1 INTRODUCTION 84
- 1.1 OBJECTIVES OF THE STUDY 84
- 1.2 MARKET DEFINITION 84
- 1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET 84
- 1.4 LIMITATIONS 87
- 1.5 MARKETS COVERED 87
2 MARKET SEGMENTATION 92
- 2.1 MARKETS COVERED 92
- 2.2 GEOGRAPHICAL SCOPE 93
- 2.3 YEARS CONSIDERED FOR THE STUDY 94
- 2.4 CURRENCY AND PRICING 94
- 2.5 DBMR TRIPOD DATA VALIDATION MODEL 95
- 2.6 MULTIVARIATE MODELLING 98
- 2.7 TREATMENT LIFELINE CURVE 98
- 2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 99
- 2.9 DBMR MARKET POSITION GRID 100
- 2.10 MARKET APPLICATION COVERAGE GRID 101
- 2.11 VENDOR SHARE ANALYSIS 102
- 2.12 SECONDARY SOURCES 103
- 2.13 ASSUMPTIONS 103
3 EXECUTIVE SUMMARY 104
4 PREMIUM INSIGHTS 107
- 4.1 KEY TRENDS 108
- 4.2 COST OF TREATMENT 109
- 4.3 KEY PLAYERS STRATEGIES 110
- 4.4 LONG TERM GROWTH APPROACH 111
5 EPIDEMIOLOGY 112
6 INDUSTRY INSIGHTS 116
- 6.1 PATENT ANALYSIS 116
- 6.2 DEMOGRAPHIC TRENDS 118
- 6.3 PATIENT FLOW DIAGRAM 119
- 6.4 KEY PRICING STRATEGIES 120
- 6.5 KEY PATIENT ENROLLMENT STRATEGIES 120
7 MARKET OVERVIEW 123
- 7.1 DRIVERS 125
  - 7.1.1 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN 125
  - 7.1.2 ADVANCES IN DRUG DEVELOPMENT FOR SJS/TEN TREATMENT 126
  - 7.1.3 INCREASING AWARENESS ABOUT THE RARE DISEASE SJS/TEN 126
  - 7.1.4 GOVERNMENT INITIATIVES FOR SJS/TEN TREATMENT 127
- 7.2 RESTRAINTS 129
  - 7.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT OF SJS/TEN 129
  - 7.2.2 LIMITED AVAILABILITY OF SPECIALIZED CARE FOR SJS/TEN TREATMENT 129
- 7.3 OPPORTUNITIES 130
  - 7.3.1 DEVELOPING EFFECTIVE AND SAFE TREATMENT FOR SJS/TEN 130
  - 7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR SJS/TEN TREATMENT 131
- 7.4 CHALLENGES 131
  - 7.4.1 STRINGENT GOVERNMENT REGULATIONS FOR APPROVAL OF TREATMENT FOR SJS/TEN 131
  - 7.4.2 LONG TERM COMPLICATIONS AND ADVERSE EFFECTS OF MEDICATIONS USED IN THE SJS/TEN TREATMENT 132
8 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY TREATMENT 133
- 8.1 OVERVIEW 134
- 8.2 MEDICATIONS 137
  - 8.2.1 ANTIHISTAMINES 138
    - 8.2.1.1 HYDROXYZINE 138
    - 8.2.1.2 FEXOFENADINE 138
  - 8.2.2 CORTICOSTEROID 139
    - 8.2.2.1 DEXAMETHASONE 139
    - 8.2.2.2 PREDNISOLONE 139
    - 8.2.2.3 METHYLPREDNISOLONE 139
    - 8.2.2.4 HYDROCORTISONE 139
    - 8.2.2.5 OTHERS 139
  - 8.2.3 ANTIBIOTICS 139
    - 8.2.3.1 NAFCILLIN 140
    - 8.2.3.2 GENTAMICIN 140
    - 8.2.3.3 OTHERS 140
  - 8.2.4 ANALGESICS 140
    - 8.2.4.1 MORPHINE 140
    - 8.2.4.2 FENTANYL CITRATE 141
    - 8.2.4.3 OTHERS 141
  - 8.2.5 ANTICOAGULANTS 141
  - 8.2.6 ANTISEPTICS 141
    - 8.2.6.1 CHLORHEXIDINE GLUCONATE 141
      - 8.2.6.1.1 PERIOGARD 142
      - 8.2.6.1.2 PERIDEX 142
      - 8.2.6.1.3 AVAGARD 142
      - 8.2.6.1.4 HIBICLENS 142
      - 8.2.6.1.5 OTHERS 142
    - 8.2.6.2 OCTENISEPT 142
    - 8.2.6.3 POLYHEXANIDE SOLUTIONS 142
    - 8.2.6.4 OTHERS 143
  - 8.2.7 INTRAVENOUS IMMUNOGLOBULIN 143
  - 8.2.8 CYCLOSPORINE 143
    - 8.2.8.1 NEORAL 143
    - 8.2.8.2 SANDIMMUNE 143
    - 8.2.8.3 OTHERS 143
  - 8.2.9 TUMOR NECROSIS FACTOR-ALPHA (TNF-Α)-BLOCKING AGENT (ETANERCEPT) 143
  - 8.2.10 OTHER TREATMENT 144
    - 8.2.10.1 CYCLOPHOSPHAMIDE 144
    - 8.2.10.2 N-ACETYLCYSTEINE 144
    - 8.2.10.3 MONOCLONAL ANTIBODIES 144
    - 8.2.10.4 THALIDOMIDE 144
- 8.3 SUPPORT CARE 144
  - 8.3.1 INTRAVENOUS (IV) FLUID AND ELECTROLYTES 145
  - 8.3.2 PAIN MANAGEMENT 146
    - 8.3.2.1 LIDOCAINE 146
    - 8.3.2.2 OTHERS 146
  - 8.3.3 NUTRITION SUPPORT 146
  - 8.3.4 ORAL CARE 146
  - 8.3.5 PLASMAPHERESIS 146
  - 8.3.6 BANDAGES 146
    - 8.3.6.1 BIOLOGICAL DRESSING 147
      - 8.3.6.1.1 ALLOGRAFT 147
      - 8.3.6.1.2 XENOGRAFT 147
      - 8.3.6.1.3 HOMOGRAFT 147
      - 8.3.6.1.4 OTHERS 147
    - 8.3.6.2 BIOSYNTHETIC DRESSING 148
    - 8.3.6.3 SILVER IMPREGNATED DRESSING 148
- 8.4 HOSPITALIZATION 148
- 8.5 ISOLATION 149
- 8.6 OINTMENTS 149
  - 8.6.1 BENZOCAINE 150
  - 8.6.2 AMERICAINE 150
  - 8.6.3 ANBESOL 150
  - 8.6.4 CHIGGEREX PLUS 150
  - 8.6.5 OTHERS 151
- 8.7 OTHERS 151
9 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DIAGNOSIS 152
- 9.1 OVERVIEW 153
- 9.2 PHYSICAL EXAM 156
- 9.3 SKIN BIOPSY 156
- 9.4 MEDICAL HISTORY 157
- 9.5 BLOOD TEST 158
  - 9.5.1 COMPLETE BLOOD COUNT 159
  - 9.5.2 ERYTHROCYTE SEDIMENTATION RATE 159
  - 9.5.3 COAGULATION STUDIES 159
  - 9.5.4 UREA AND ELECTROLYTES 160
  - 9.5.5 LIVER FUNCTION TEST 160
- 9.6 CULTURES 160
- 9.7 OTHERS 161
10 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY CAUSE 162
- 10.1 OVERVIEW 163
- 10.2 SPECIFIC TREATMENT 166
- 10.3 INFECTION 166
- 10.4 OTHERS 167
11 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 168
- 11.1 OVERVIEW 169
- 11.2 ORAL 172
- 11.3 PARENTERAL 172
  - 11.3.1 INTRAVENOUS 173
  - 11.3.2 SUBCUTANEOUS 173
  - 11.3.3 OTHERS 173
- 11.4 TOPICAL 173
  - 11.4.1 OINTMENTS 174
  - 11.4.2 SOLUTION 174
  - 11.4.3 CREAMS 175
  - 11.4.4 OTHERS 175
- 11.5 OTHERS 175
12 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DRUG TYPE 176
- 12.1 OVERVIEW 177
- 12.2 BRANDED 180
  - 12.2.1 NEORAL 181
  - 12.2.2 SANDIMMUNE 181
  - 12.2.3 VISTARIL 181
  - 12.2.4 DURAMORPH 181
  - 12.2.5 FENTORA 181
  - 12.2.6 ENBREL 181
  - 12.2.7 OTHERS 181
- 12.3 GENERIC 181
13 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY THERAPY TYPE 183
- 13.1 OVERVIEW 184
- 13.2 COMBINATION THERAPY 187
- 13.3 MONOTHERAPY 187
14 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY PATIENT TYPE 189
- 14.1 OVERVIEW 190
- 14.2 GERIATRIC 193
  - 14.2.1 FEMALE 194
  - 14.2.2 MALE 194
- 14.3 ADULT 194
  - 14.3.1 FEMALE 195
  - 14.3.2 MALE 195
- 14.4 PEDIATRIC 195
15 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY END USER 197
- 15.1 OVERVIEW 198
- 15.2 HOSPITALS 201
- 15.3 SPECIALTY CLINICS 201
- 15.4 AMBULATORY SURGICAL CENTER 202
- 15.5 HOMECARE SETTING 203
- 15.6 OTHERS 203
16 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY DISTRIBUTION CHANNEL 205
- 16.1 OVERVIEW 206
- 16.2 RETAIL PHARMACIES 209
  - 16.2.1 HOSPITAL ASSOCIATED PHARMACIES 210
  - 16.2.2 DRUG STORE 210
  - 16.2.3 ONLINE PHARMACIES 210
- 16.3 DIRECT TENDERS 210
- 16.4 OTHERS 211
17 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY REGION 212
- 17.1 MIDDLE EAST AND AFRICA 213
  - 17.1.1 SOUTH AFRICA 229
  - 17.1.2 SAUDI ARABIA 240
  - 17.1.3 BAHRAIN 251
  - 17.1.4 U.A.E 262
  - 17.1.5 KUWAIT 273
  - 17.1.6 OMAN 283
  - 17.1.7 QATAR 294
  - 17.1.8 EGYPT 305
  - 17.1.9 ISRAEL 315
  - 17.1.10 REST OF MIDDLE EAST AND AFRICA 326
18 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, COMPANY LANDSCAPE 327
- 18.1 COMPANY SHARE ANALYSIS: MIDDLE EAST AND AFRICA 327
19 SWOT ANALYSIS 328
20 COMPANY PROFILE 329
- 20.1 PFIZER INC 329
  - 20.1.1 COMPANY SNAPSHOT 329
  - 20.1.2 REVENUE ANALYSIS 329
  - 20.1.3 COMPANY SHARE ANALYSIS 330
  - 20.1.4 PRODUCT PORTFOLIO 330
  - 20.1.5 RECENT DEVELOPMENT 330
- 20.2 NOVARTIS AG 331
  - 20.2.1 COMPANY SNAPSHOT 331
  - 20.2.2 REVENUE ANALYSIS 331
  - 20.2.3 COMPANY SHARE ANALYSIS 332
  - 20.2.4 PRODUCT PORTFOLIO 332
  - 20.2.5 RECENT DEVELOPMENT 332
- 20.3 MERCK & CO., INC 333
  - 20.3.1 COMPANY SNAPSHOT 333
  - 20.3.2 REVENUE ANALYSIS 333
  - 20.3.3 COMPANY SHARE ANALYSIS 334
  - 20.3.4 PRODUCT PORTFOLIO 334
  - 20.3.5 RECENT DEVELOPMENT 334
- 20.4 AMNEAL PHARMACEUTICAL LLC 335
  - 20.4.1 COMPANY SNAPSHOT 335
  - 20.4.2 REVENUE ANALYSIS 335
  - 20.4.3 COMPANY SHARE ANALYSIS 336
  - 20.4.4 PRODUCT PORTFOLIO 336
  - 20.4.5 RECENT DEVELOPMENT 336
- 20.5 AMGEN INC 337
  - 20.5.1 COMPANY SNAPSHOT 337
  - 20.5.2 REVENUE ANALYSIS 337
  - 20.5.3 PRODUCT PORTFOLIO 338
  - 20.5.4 RECENT DEVELOPMENT 338
- 20.6 ADVACARE PHARMA 339
  - 20.6.1 COMPANY SNAPSHOT 339
  - 20.6.2 PRODUCT PORTFOLIO 339
  - 20.6.3 RECENT DEVELOPMENT 339
- 20.7 BD 340
  - 20.7.1 COMPANY SNAPSHOT 340
  - 20.7.2 REVENUE ANALYSIS 340
  - 20.7.3 PRODUCT PORTFOLIO 341
  - 20.7.4 RECENT DEVELOPMENT 341
- 20.8 CARDINAL HEALTH 342
  - 20.8.1 COMPANY SNAPSHOT 342
  - 20.8.2 REVENUE ANALYSIS 342
  - 20.8.3 PRODUCT PORTFOLIO 343
  - 20.8.4 RECENT DEVELOPMENT 343
- 20.9 COLGATE-PALMOLIVE COMPANY 344
  - 20.9.1 COMPANY SNAPSHOT 344
  - 20.9.2 REVENUE ANALYSIS 344
  - 20.9.3 PRODUCT PORTFOLIO 345
  - 20.9.4 RECENT DEVELOPMENT 345
- 20.10 EUGIA (SUBSIDIARY OF AUROBINDO PHARMA) 346
  - 20.10.1 COMPANY SNAPSHOT 346
  - 20.10.2 REVENUE ANALYSIS 346
  - 20.10.3 PRODUCT PORTFOLIO 347
  - 20.10.4 RECENT DEVELOPMENT 347
- 20.11 ICPA HEALTH PRODUCTS LTD 348
  - 20.11.1 COMPANY SNAPSHOT 348
  - 20.11.2 PRODUCT PORTFOLIO 348
  - 20.11.3 RECENT DEVELOPMENT 348
- 20.12 3M 349
  - 20.12.1 COMPANY SNAPSHOT 349
  - 20.12.2 REVENUE ANALYSIS 349
  - 20.12.3 PRODUCT PORTFOLIO 350
  - 20.12.4 RECENT DEVELOPMENT 350
- 20.13 MOLNLYCKE HEALTH CARE AB 351
  - 20.13.1 COMPANY SNAPSHOT 351
  - 20.13.2 PRODUCT PORTFOLIO 351
  - 20.13.3 RECENT DEVELOPMENT 351
- 20.14 PURDUE PHARMA L.P 352
  - 20.14.1 COMPANY SNAPSHOT 352
  - 20.14.2 PRODUCT PORTFOLIO 352
  - 20.14.3 RECENT DEVELOPMENT 352
- 20.15 SCHULKE & MAYR GMBH 353
  - 20.15.1 COMPANY SNAPSHOT 353
  - 20.15.2 PRODUCT PORTFOLIO 353
  - 20.15.3 RECENT DEVELOPMENT 353
- 20.16 SMITH + NEPHEW 354
  - 20.16.1 COMPANY SNAPSHOT 354
  - 20.16.2 REVENUE ANALYSIS 354
  - 20.16.3 PRODUCT PORTFOLIO 355
  - 20.16.4 RECENT DEVELOPMENT 355
- 20.17 XTTRIUM LABORATORIES 356
  - 20.17.1 COMPANY SNAPSHOT 356
  - 20.17.2 PRODUCT PORTFOLIO 356
  - 20.17.3 RECENT DEVELOPMENT 356
21 QUESTIONNAIRE 357
22 RELATED REPORTS 361

MEA SJS TEN Treatment Market - Industry Trends and Forecast to 2030 ‐ Pharmaceutical_LifeSciense Market

MEA SJS TEN Treatment Market - Industry Trends and Forecast to 2030 ‐ Pharmaceutical_LifeSciense Market

Abstract

Summary

Table of Contents

1 INTRODUCTION 84

1.1 OBJECTIVES OF THE STUDY 84

1.2 MARKET DEFINITION 84

1.3 OVERVIEW OF THE MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET 84

1.4 LIMITATIONS 87

1.5 MARKETS COVERED 87

2 MARKET SEGMENTATION 92

2.1 MARKETS COVERED 92

2.2 GEOGRAPHICAL SCOPE 93

2.3 YEARS CONSIDERED FOR THE STUDY 94

2.4 CURRENCY AND PRICING 94

2.5 DBMR TRIPOD DATA VALIDATION MODEL 95

2.6 MULTIVARIATE MODELLING 98

2.7 TREATMENT LIFELINE CURVE 98

2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 99

2.9 DBMR MARKET POSITION GRID 100

2.10 MARKET APPLICATION COVERAGE GRID 101

2.11 VENDOR SHARE ANALYSIS 102

2.12 SECONDARY SOURCES 103

2.13 ASSUMPTIONS 103

3 EXECUTIVE SUMMARY 104

4 PREMIUM INSIGHTS 107

4.1 KEY TRENDS 108

4.2 COST OF TREATMENT 109

4.3 KEY PLAYERS STRATEGIES 110

4.4 LONG TERM GROWTH APPROACH 111

5 EPIDEMIOLOGY 112

6 INDUSTRY INSIGHTS 116

6.1 PATENT ANALYSIS 116

6.2 DEMOGRAPHIC TRENDS 118

6.3 PATIENT FLOW DIAGRAM 119

6.4 KEY PRICING STRATEGIES 120

6.5 KEY PATIENT ENROLLMENT STRATEGIES 120

7 MARKET OVERVIEW 123

7.1 DRIVERS 125

7.1.1 INCREASING PREVALENCE AND INCIDENCE OF SJS/TEN 125

7.1.2 ADVANCES IN DRUG DEVELOPMENT FOR SJS/TEN TREATMENT 126

7.1.3 INCREASING AWARENESS ABOUT THE RARE DISEASE SJS/TEN 126

7.1.4 GOVERNMENT INITIATIVES FOR SJS/TEN TREATMENT 127

7.2 RESTRAINTS 129

7.2.1 HIGH COST ASSOCIATED WITH THE TREATMENT OF SJS/TEN 129

7.2.2 LIMITED AVAILABILITY OF SPECIALIZED CARE FOR SJS/TEN TREATMENT 129

7.3 OPPORTUNITIES 130

7.3.1 DEVELOPING EFFECTIVE AND SAFE TREATMENT FOR SJS/TEN 130

7.3.2 INCREASING RESEARCH AND DEVELOPMENT ACTIVITIES FOR SJS/TEN TREATMENT 131

7.4 CHALLENGES 131

7.4.1 STRINGENT GOVERNMENT REGULATIONS FOR APPROVAL OF TREATMENT FOR SJS/TEN 131

7.4.2 LONG TERM COMPLICATIONS AND ADVERSE EFFECTS OF MEDICATIONS USED IN THE SJS/TEN TREATMENT 132

8 MIDDLE EAST AND AFRICA SJS/TEN TREATMENT MARKET, BY TREATMENT 133

8.1 OVERVIEW 134

8.2 MEDICATIONS 137

8.2.1 ANTIHISTAMINES 138

8.2.2 CORTICOSTEROID 139

8.2.3 ANTIBIOTICS 139

8.2.4 ANALGESICS 140

8.2.5 ANTICOAGULANTS 141

8.2.6 ANTISEPTICS 141

8.2.7 INTRAVENOUS IMMUNOGLOBULIN 143

8.2.8 CYCLOSPORINE 143

8.2.9 TUMOR NECROSIS FACTOR-ALPHA (TNF-Α)-BLOCKING AGENT (ETANERCEPT) 143

8.2.10 OTHER TREATMENT 144

8.3 SUPPORT CARE 144

8.3.1 INTRAVENOUS (IV) FLUID AND ELECTROLYTES 145

8.3.2 PAIN MANAGEMENT 146

8.3.3 NUTRITION SUPPORT 146

8.3.4 ORAL CARE 146

8.3.5 PLASMAPHERESIS 146

8.3.6 BANDAGES 146

8.4 HOSPITALIZATION 148

8.5 ISOLATION 149

8.6 OINTMENTS 149

8.6.1 BENZOCAINE 150

8.6.2 AMERICAINE 150

8.6.3 ANBESOL 150

8.6.4 CHIGGEREX PLUS 150